Growth Hormone Secretagogues Complete Guide: GHRH, GHRPs, and MK-677

Growth hormone secretagogues (GHS) are a class of compounds that stimulate the pituitary gland to release growth hormone (GH) through endogenous pathways, rather than introducing exogenous GH directly. This distinction matters enormously: by working through the body's own regulatory mechanisms, secretagogues preserve physiological feedback loops that prevent the pituitary from releasing dangerously excessive amounts of GH. Understanding the two primary categories of GHS — growth hormone-releasing hormone (GHRH) analogs and growth hormone-releasing peptides (GHRPs) — along with the oral secretagogue MK-677, provides a complete picture of the field.

Why Growth Hormone Matters

Growth hormone is a 191-amino acid protein produced by somatotroph cells in the anterior pituitary. Its downstream effects are widespread:

• IGF-1 production: GH stimulates the liver to produce insulin-like growth factor 1 (IGF-1), the primary mediator of GH's anabolic effects on muscle, bone, and connective tissue
• Lipolysis: GH stimulates fat breakdown, particularly visceral fat
• Protein synthesis: GH directly and indirectly promotes nitrogen retention and muscle protein synthesis
• Bone density: GH increases osteoblast activity and bone mineral density
• Cellular repair: GH accelerates tissue regeneration and wound healing

GH secretion naturally declines with age — a phenomenon called somatopause. By age 60, most adults secrete only 25–30% of the GH they did at age 20. This decline is associated with increased body fat, reduced lean mass, impaired recovery, and changes in sleep architecture. Secretagogues are studied as a way to restore more youthful GH pulsatility without the regulatory and physiological concerns of exogenous GH.

GHRH Analogs: Signaling the Pituitary Directly

Growth hormone-releasing hormone is a 44-amino acid peptide produced in the hypothalamus. It travels to the anterior pituitary where it binds GHRH receptors (GHRHR) on somatotroph cells, stimulating GH synthesis and release. GHRH also increases the number of somatotrophs over time through its growth-promoting effects on the pituitary.

Sermorelin (GHRH 1-29): The first therapeutically used GHRH analog, sermorelin contains the first 29 amino acids of the 44-amino acid GHRH sequence — the minimum required for full receptor binding and activity. It is FDA-approved for pediatric GH deficiency diagnosis and has been used off-label in adult anti-aging medicine. Its half-life of approximately 10–20 minutes requires frequent administration.

CJC-1295 without DAC (Mod GRF 1-29): An optimized version of GHRH(1-29) with four amino acid substitutions that protect against DPP-IV cleavage and oxidation. These substitutions extend the half-life to approximately 30 minutes while preserving full receptor activity. This is one of the most widely used GHRH analogs in research contexts.

CJC-1295 with DAC: The drug affinity complex (DAC) modification attaches a reactive lysine side chain that covalently binds albumin in the bloodstream after injection. This dramatically extends the half-life to 6–8 days, creating a steady elevation in GH baseline rather than the pulsatile pattern of shorter analogs. The prolonged stimulation raises questions about whether continuous GHRH signaling is as physiologically favorable as pulsatile release.

Tesamorelin: An FDA-approved GHRH analog (brand name Egrifta) indicated for HIV-associated lipodystrophy. It is a modified GHRH(1-44) with a trans-3-hexenoic acid group added at the N-terminus. Tesamorelin has a half-life of approximately 26 minutes and has shown benefits in reducing visceral fat in clinical trials.

The GHRP Family: Ghrelin Receptor Agonists

Growth hormone-releasing peptides work through an entirely different mechanism. They are agonists of the ghrelin receptor (GHSR-1a) — a GPCR found in the hypothalamus and pituitary that, when activated, stimulates GH release through two pathways:

1. Direct stimulation of somatotrophs
2. Suppression of somatostatin (the GH-inhibiting hormone) at the hypothalamus

Because GHRPs and GHRH work through different receptors, combining them produces synergistic rather than merely additive GH release. This is the scientific basis for stacking strategies that combine a GHRH analog with a GHRP. For a full comparison of these two pathways, see our GHRH vs GHRP peptides guide.

GHRP-6: The original GHRP, GHRP-6 is a hexapeptide that produces robust GH release. Its primary limitation is significant appetite stimulation — a direct consequence of its ghrelin receptor agonism in the gut (ghrelin is the "hunger hormone"). Some researchers actually use this property intentionally for appetite support in underweight or muscle-wasting states.

GHRP-2: More potent than GHRP-6 for GH release with somewhat less appetite stimulation. GHRP-2 also causes greater cortisol and prolactin elevation than other GHRPs, which is a consideration for long-term use.

Ipamorelin: The most selective GHRP in common use. Ipamorelin produces GH release with minimal effect on cortisol, prolactin, or appetite — making it the preferred GHRP for most research contexts. Its selectivity is due to its specific interaction profile at the GHSR-1a receptor. Half-life is approximately 2 hours.

Hexarelin: The most potent GHRP for GH release, but it carries the highest risk of cortisol and prolactin elevation and shows faster desensitization of the GHSR-1a receptor with repeated dosing than other GHRPs. It also has cardioprotective effects independent of GH release, mediated through CD36 receptors.

Examorelin: Used primarily in clinical contexts for GH stimulation testing and cachexia.

MK-677 (Ibutamoren): The Oral GH Secretagogue

MK-677, also known as ibutamoren, is not technically a peptide — it is a non-peptide peptidomimetic. However, it is the most clinically studied oral GH secretagogue, and it belongs in any comprehensive discussion of the field.

MK-677 is a potent, long-acting GHSR-1a agonist that mimics ghrelin's action on the receptor. Unlike peptide GHRPs, it survives oral administration and is active when taken by mouth. Its half-life of approximately 24 hours means once-daily dosing is effective.

Clinical research findings:

• Increases GH pulse amplitude and IGF-1 levels dose-dependently (doses of 10–25 mg studied in clinical trials)
• Improves bone mineral density in elderly subjects
• Increases lean mass while having variable effects on fat mass
• Significantly improves slow-wave sleep (deep sleep)
• Does not suppress endogenous GH secretion with continued use at studied doses

Considerations: MK-677 increases appetite substantially (again, via ghrelin receptor in the gut) and causes some fluid retention due to GH's effect on aldosterone and natriuretic peptides. Long-term use requires monitoring of fasting glucose and insulin sensitivity.

Comparing the Major GH Secretagogues

| Compound | Class | Half-Life | Route | GH Pulse Pattern | Appetite Effect | |---|---|---|---|---|---| | Sermorelin | GHRH analog | 10–20 min | SubQ | Pulsatile | Minimal | | Mod GRF 1-29 | GHRH analog | 30 min | SubQ | Pulsatile | Minimal | | CJC-1295 DAC | GHRH analog | 6–8 days | SubQ | Continuous baseline | Minimal | | Ipamorelin | GHRP | 2 hours | SubQ | Pulsatile | Low | | GHRP-2 | GHRP | 1–2 hours | SubQ | Pulsatile | Moderate | | GHRP-6 | GHRP | 1–2 hours | SubQ | Pulsatile | High | | MK-677 | GH secretagogue | 24 hours | Oral | Both baseline + pulses | High |

Mechanisms That Govern GH Release

GH secretion is regulated by a push-pull system between hypothalamic GHRH (stimulatory) and somatostatin (inhibitory). The pituitary integrates these opposing signals, releasing GH in pulses — typically 6–12 pulses per day, with the largest occurring during slow-wave sleep.

Secretagogues amplify this pulsatile pattern by:

1. Increasing pulse amplitude via GHRH receptor stimulation or ghrelin receptor stimulation
2. Reducing somatostatin tone via GHSR-1a signaling in the hypothalamus
3. Preserving feedback loops — IGF-1 and GH itself feed back to suppress further release, preventing runaway GH elevation

This preserved feedback is a key safety feature of secretagogues relative to exogenous GH administration. IGF-1 levels typically increase 1.5–2.5x above baseline with well-designed secretagogue protocols — a meaningful increase, but not the supraphysiological elevations possible with direct GH injection.

Clinical and Research Context

Growth hormone secretagogues have been extensively studied for:

• Age-related GH decline (somatopause)
• GH deficiency in adults and children
• HIV-associated wasting and lipodystrophy
• Osteoporosis and bone density
• Sleep quality and cognitive function
• Body composition optimization

While secretagogue peptides are widely studied and commercially available as research compounds, regulatory status varies by country and application. Tesamorelin and sermorelin have FDA-approved clinical uses; other GHRPs and GHRH analogs remain in the research category.

Frequently Asked Questions

Q: What is the main difference between a GHRH analog and a GHRP? GHRH analogs bind the GHRH receptor and directly stimulate pituitary somatotrophs. GHRPs bind the ghrelin receptor (GHSR-1a) and work through both direct pituitary stimulation and suppression of somatostatin. These complementary mechanisms explain why combining them produces synergistic GH release.

Q: Is MK-677 a steroid or peptide? MK-677 is neither. It is a small non-peptide molecule (a spiroindoline compound) that mimics ghrelin at the GHSR-1a receptor. It has no hormonal structure and no anabolic steroid activity. It is orally bioavailable, which distinguishes it from all peptide GHS.

Q: How long does it take to see results from GH secretagogues? GH pulses increase within the first dose. However, IGF-1 takes 2–4 weeks to rise significantly, and the most meaningful outcomes (body composition changes, improved recovery, changes in skin and connective tissue quality) typically require 8–16 weeks of consistent use.

Q: Does continuous GHRH stimulation (CJC-1295 with DAC) reduce the pituitary's ability to respond over time? This is a legitimate concern. Chronic GHRH stimulation can cause somatotroph desensitization. Pulsatile protocols mimicking normal physiology are generally preferred for long-term use to prevent downregulation.

Q: Can GH secretagogues be used by people with normal GH levels? Secretagogues can increase GH above normal baseline ranges. Individuals with already-normal GH may see proportionally smaller absolute increases. The safety and long-term effects of supraphysiological GH elevation in otherwise healthy individuals is an active research question.